Update shared on 19 Nov 2025
Fair value Decreased 13%The analyst price target for HLS Therapeutics has increased from C$6 to C$7. This reflects analysts’ confidence in the company’s improving financial performance and ongoing strategic initiatives.
Analyst Commentary
Recent analyst updates reflect evolving perspectives on HLS Therapeutics’ outlook. Price targets and ratings have been adjusted in response to the company’s operational performance and strategic advancements.
Bullish Takeaways
- Bullish analysts highlight the continued recovery in adjusted EBITDA. This supports a higher valuation and an improved price target.
- Recent financial activities such as share buybacks and debt reduction are noted as indicators of strong cash flow management and strategic discipline.
- The expansion of HLS Therapeutics’ portfolio signals growth potential and enhances the company’s long-term prospects, adding support to an Outperform outlook.
- Confidence in the current execution of business initiatives underpins the rationale for an upward revision of the price target.
Bearish Takeaways
- Some caution remains regarding the company’s ability to sustain EBITDA improvements over multiple quarters.
- Analysts identify ongoing competitive pressures and market dynamics that could impact further margin expansion.
- While strategic initiatives have yielded progress, there is vigilance over the pace and consistency of future growth.
What's in the News
- HLS Therapeutics received Health Canada approval to market NILEMDO for reducing LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch is expected in the second quarter of 2026. Heart disease remains a critical health concern in Canada, affecting 2.6 million adults and being the second leading cause of death. (Key Developments)
- The company updated its 2025 earnings guidance, projecting consolidated revenue between $55 million and $56 million. Vascepa revenue is expected to grow in the mid-teen percentages, while Canada Clozaril revenue is now forecast to decline by 4% to 5%. U.S. Clozaril revenue is expected to decrease by 2% to 4% year-over-year, and royalty revenue is expected to drop by 50% to 60%. (Key Developments)
Valuation Changes
- Fair Value has fallen from CA$7.41 to CA$6.42, reflecting a more conservative outlook on the company’s intrinsic valuation.
- Discount Rate has risen slightly from 5.97% to 6.12%, indicating increased perceived risk or market volatility.
- Revenue Growth expectation increased modestly from 5.20% to 5.35%, suggesting a minor upgrade in anticipated sales momentum.
- Net Profit Margin has risen significantly from 1.20% to 2.85%, pointing to improved efficiency and profitability projections.
- Future P/E ratio has declined markedly from 334.37x to 103.12x, which indicates lower projected earnings multiples and potential valuation normalization.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.